DOJ Finds Yale Medical School Discriminated Against White and Asian Applicants

The DOJ's Year-Long Probe into Yale School of Medicine Admissions

The United States Department of Justice (DOJ) Civil Rights Division has thrust Yale School of Medicine (YSM), one of the nation's premier institutions for training physicians, into the spotlight with findings from a comprehensive investigation. Launched in the wake of the Supreme Court's landmark 2023 decision in Students for Fair Admissions, Inc. v. President and Fellows of Harvard College—commonly known as SFFA v. Harvard—the probe examined whether YSM's admissions processes complied with federal anti-discrimination laws. Title VI of the Civil Rights Act of 1964 prohibits recipients of federal funding, including universities, from discriminating on the basis of race, color, or national origin.

Over the course of a year, DOJ investigators requested and analyzed thousands of documents from Yale, including applicant data, internal emails, policy memos, and admissions committee presentations. The review focused on incoming classes from 2023 through 2025, scrutinizing metrics like undergraduate grade point averages (GPAs) and Medical College Admission Test (MCAT) scores alongside qualitative evaluations. The resulting letter of findings, released on May 14, 2026, concludes that YSM violated Title VI by intentionally incorporating race into admissions decisions, systematically disadvantaging white and Asian applicants in favor of Black and Hispanic candidates.

Statistical Evidence of Admissions Disparities

Central to the DOJ's case are stark statistical disparities in the academic credentials of admitted students across racial groups. While YSM admits around 100 students annually from thousands of applicants, the data reveals consistent patterns where Black and Hispanic matriculants entered with median GPAs and MCAT scores several points below their white and Asian peers.

Similar gaps persisted in 2024 and 2025 classes, with Black admitted students' MCAT percentiles hovering at 94-95 compared to 99-100 for whites and Asians. Applicant-level analysis showed even more pronounced effects: a Black applicant could have up to 29 times higher odds of securing an interview than an equally qualified Asian applicant. These outcomes, according to the DOJ, stem not from random variation but from deliberate race-conscious practices in a highly competitive, zero-sum admissions environment.

For context, the MCAT, administered by the Association of American Medical Colleges (AAMC), ranges from 472 to 528, with percentiles reflecting national performance. A 5-point gap translates to significant differences in applicant pools, yet YSM's process allowed lower-scoring candidates from preferred groups to advance.

Internal Documents Revealing Race-Conscious Strategies

YSM's own materials provided damning evidence of intent. Post-SFFA presentations discussed 'race-neutral' proxies like socioeconomic status adjustments to boost Underrepresented in Medicine (URiM) enrollment, drawing from models at schools like the University of California, Davis. One retreat slide warned against racial stereotypes while advocating for increased minority representation, echoing concerns the Supreme Court deemed unconstitutional.

Emails and guidance circulated the AAMC's holistic review framework, which explicitly lists race as a factor, even after the ruling. Verbal directives allegedly instructed committees to consider applicants' race/ethnicity, avoiding written trails. The DOJ letter highlights a 2024 'Admissions post-SCOTUS' slide and redacted policies as attempts to skirt the law. You can review the full DOJ letter of findings for these document references.

Yale's Official Response and Defense

Yale spokesperson Karen Peart issued a measured statement: 'We will carefully review the Department of Justice's letter. Yale School of Medicine is confident in the rigorous admissions process we follow.' Dean Nancy J. Brown emphasized that admitted students exhibit 'exceptional academic achievement and personal commitment,' underscoring holistic review beyond numbers.

In keeping with past responses to federal scrutiny, Yale maintains its practices align with mission-driven goals, including training physicians for diverse populations. No admissions changes have been announced pending review.

Photo by Dylan Klingler on Unsplash

Post-SFFA Landscape in Higher Education Admissions

The SFFA ruling invalidated race as a 'plus factor' in undergraduate and graduate admissions, mandating individualized consideration without stereotypes. Yet, medical schools face unique pressures: the physician shortage, health disparities linked to provider-patient racial concordance, and AAMC calls for URiM increases. Post-2023, URiM matriculations dipped from 24% to 20% nationally, prompting innovations like expanded interviews and PREview exams assessing empathy.

However, the Trump administration's renewed DOJ focus signals enforcement against perceived proxies, extending beyond undergrad to professional programs. This echoes 2020 probes into Yale's undergraduate admissions, dropped under Biden but revived in spirit.

Parallel Investigations at UCLA and Beyond

YSM is not alone. Just days prior, DOJ issued similar findings against UCLA's David Geffen School of Medicine, citing comparable MCAT/GPA gaps. A lawsuit there alleges intentional discrimination via holistic tools. Other targets include programs using DEI metrics, with potential for funding cuts under Title VI.

These cases highlight a federal crackdown, contrasting state bans like California's Proposition 209, where schools achieved diversity race-neutrally—offering models for compliance. Explore the DOJ press release for official parallels.

Implications for Medical Education and Workforce Diversity

Medical schools grapple with balancing merit and mission. Proponents of diversity cite studies showing same-race providers improve outcomes for underserved patients, vital amid shortages in rural and minority communities. Critics argue lower-bar admissions risk quality, though data shows low-MCAT students (498-501) succeed at 94% first-year rates.

• Risk of lawsuits and enrollment shifts if race proxies fail scrutiny.
• Push toward race-neutral tools: geography, first-gen status, economic need.
• Accreditation changes stripping 'health equity' mandates.
• Broader higher ed chilling effect on DEI initiatives.

Diverse Stakeholder Perspectives

Experts diverge. AAMC's Javarro Russell defends non-academic factors for physician success. Harvard's Gregory Curfman notes MCAT limits, while sociologist Carson Byrd decries 'meritocracy' myths ignoring inequities. Legal scholars like Carmel Shachar highlight med schools' public health role.

Student groups express mixed views: some celebrate scrutiny for fairness, others fear diversity erosion. Faculty worry about politicization amid antisemitism probes elsewhere at Yale.

Photo by Laura Rivera on Unsplash

Future Outlook and Pathways Forward

DOJ seeks voluntary resolution: cease race use, monitor compliance, report data. Non-compliance risks enforcement, funding loss. Yale may litigate or reform, piloting proxies upheld in courts.

For higher ed, this accelerates race-neutral innovation—cluster hires, outreach, apprenticeships. Long-term, expect SCOTUS clarification on proxies, reshaping professional admissions. Institutions prioritizing transparency and merit stand resilient.

Aspiring med students: Bolster apps with research, volunteering; target schools with proven neutral success. Explore opportunities via platforms connecting to higher education jobs and faculty insights.